IL17A and pulmonary emphysema: IL-17A is implicated in COPD-associated pathogenic responses, including emphysema, lymphoid neogenesis, corticosteroid resistance, dysbiosis, mucus hypersecretion, and ongoing inflammation despite smoking cessation (12–19).